Similar articles

• The Food and Drug Administration and patent law at a crossroads: the listing of polymorph patents as a barrier to generic drug entry.

  Srivastava D. Srivastava D. Food Drug Law J. 2004;59(2):339-54. Food Drug Law J. 2004. PMID: 15298015 No abstract available.
• Implementation of the biosimilar pathway: economic and policy issues.

  Grabowski H, Long G, Mortimer R. Grabowski H, et al. Seton Hall Law Rev. 2011;41(2):511-57. Seton Hall Law Rev. 2011. PMID: 21739758 No abstract available.
• The generic drug approval process.

  Rheinstein PH. Rheinstein PH. Am Fam Physician. 1993 Dec;48(8):1357-60. Am Fam Physician. 1993. PMID: 8249762 No abstract available.
• Generic drugs: the Canadian perspective.

  McGilveray IJ, Gallicano K. McGilveray IJ, et al. Transplant Proc. 1999 May;31(3A Suppl):16S-18S. doi: 10.1016/s0041-1345(99)00107-4. Transplant Proc. 1999. PMID: 10330953 Review. No abstract available.
• [Levothyroxine and the problem of interchangeability of drugs with narrow therapeutic index].

  Ward LS. Ward LS. Arq Bras Endocrinol Metabol. 2011 Oct;55(7):429-34. doi: 10.1590/s0004-27302011000700001. Arq Bras Endocrinol Metabol. 2011. PMID: 22147090 Review. Portuguese.